Surgical intervention is used to treat dynamic left ventricular outflow tract obstruction (LVOTO) in hypertrophic cardiomyopathy. This study assesses the effect of different surgical strategies on long-term mortality and morbidity. 
Introduction
Hypertrophic cardiomyopathy (HCM) is a common myocardial disorder usually inherited as an autosomal dominant trait that causes premature death from heart failure (HF), stroke and ventricular arrhythmia.
1 -6 Many patients experience debilitating symptoms due to obstruction of the left ventricular outflow tract (LVOT) caused by contact between the mitral valve (MV) leaflet(s) and the interventricular septum during ventricular systole. Factors 
predisposing to this abnormal movement of the valve include altered septal geometry, elongation of the mitral leaflets and malpositioning of the papillary muscles and mitral chordae. 7 -12 Left ventricular outflow tract obstruction (LVOTO) typically increases with increased ventricular contractility and so negatively inotropic drugs such as -blockers, calcium antagonists and disopyramide are used as first-line therapy in symptomatic patients. 4 However, some patients continue to experience symptoms despite medical therapy and may be candidates for surgical interventions that reduce the thickness of the interventricular septum or alter the MV or submitral apparatus.
Many studies have shown that septal myectomy (SM) in which the thickness of the basal septum is reduced by removal of muscle via an aortic approach results in relief of obstruction and good long-term outcomes. 13 -19 In patients with marked mitral leaflet elongation, SM has been combined with one of several adjunctive procedures including MV repair and MV replacement. 20 -24 However, there are few data on their safety and long-term benefit compared to SM alone.
The aim in this retrospective analysis was to compare and contrast the short-and long-term outcomes in patients undergoing a range of different surgical approaches for the relief of LVOTO.
Methods

Study design
This was an observational cohort study comprising all patients with HCM undergoing surgical treatment for LVOTO and followed up at a specialist cardiomyopathy clinic located sequentially at St George's Hospital (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) , The Heart Hospital, University College London (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) and St Bartholomew's Hospital (2015 to present). The majority of patients were operated on by three surgeons (C. McG ., V.T., V.C. ) . HCM was defined as a wall thickness ≥ 15 mm in any left ventricular (LV) myocardial segment in the absence of other abnormal loading conditions or ≥13 mm in the presence of a family history of HCM. 2 Surgical intervention was considered in accordance with international guidelines in patients with drug refractory symptomatic LVOTO. This eligibility was defined as a LVOT gradient ≥50 mmHg and was documented under resting conditions or provoked using Valsalva manoeuvre and exercise echocardiography when clinically indicated. 2 Patients with rare phenocopies of HCM including lysosomal storage diseases, metabolic conditions or malformations were excluded. Eight patients undergoing a SM also had aortic stenosis (AS) and received an aortic valve (AV) replacement. These patients were not included in the analysis. Ten patients received a concomitant AV replacement for underlying aortic regurgitation or mixed AV disease with mild AS only and were included in the study.
Clinical assessment
All patients were assessed in a specialist clinic and their data were stored on a relational database. Background history was documented including previous arrhythmia or cardiovascular complications. Atrial fibrillation (AF) and ventricular tachycardia documented on 12-lead electrocardiogram (ECG) or prolonged ECG monitoring and a family history of HCM or sudden cardiac death (SCD) were defined as in previous studies. 5, 6 Clinical assessment included documentation of New York Heart Association (NYHA) class, a 12-lead ECG and a transthoracic echocardiogram. Maximum LV wall thickness, LV ejection fraction by visual assessment, left atrial dimensions and LVOT pressure gradients at rest and with Valsalva provocation were documented. Exercise stress echocardiography using a bicycle ergometer was performed on clinical grounds to detect a provoked gradient when no resting LVOT gradient was documented. Cardiopulmonary exercise testing (CPET) was carried out using a bicycle ergometer in accordance with published methods. 6 Peak oxygen consumption, percentage target heart rate achieved, and systolic and diastolic blood pressure responses to
exercise were documented. Prior to surgery, patients were presented at a joint cardiothoracic conference to a team of cardiac surgeons and cardiologists specialising in inherited cardiovascular disease to determine the most suitable management plan. Individuals with significant LVOTO who were considered unsuitable for SM typically had mild hypertrophy or co-existent severe MV disease unrelated to obstruction and were considered for alternative surgical approaches.
Follow-up
Following surgical intervention, patients were assessed postoperatively by surgical and medical teams at 6 weeks and then at regular intervals based on their clinical condition. For the purposes of this analysis, clinical data were reviewed from follow-up clinics at 1, 5 and 10 years post-operatively. Perioperative complications and death were defined as events occurring during a perioperative stay or within the first 30 days post-operatively. Long-term outcomes (occurring at least 30 days after surgical intervention) used in the analysis were: stroke or transient ischaemic attacks, new onset AF, permanent pacemaker (PPM) implantation and HF hospitalisations, defined as an acute admission to hospital with shortness of breath and/or fluid overload requiring treatment with intravenous diuretics. Patients were included if at least 1 year had lapsed since their surgery and clinical and echocardiographic data were available.
Study endpoints
The primary survival endpoint was all-cause mortality. Secondary endpoints were cardiovascular death, SCD, aborted SCD, repeat cardiovascular operation and heart transplantation. Cardiovascular death was defined as death secondary to SCD, stroke or HF. SCD was defined as witnessed sudden death within 1 h of the onset of new symptoms or nocturnal deaths with no recent history of worsening symptoms. Aborted SCD was defined as successful defibrillation with spontaneous restoration of circulation. This definition included implantable cardioverter defibrillator (ICD) shocks due to ventricular arrhythmias. HF death was defined as death preceded by signs and symptoms of HF of >1 h duration or cardiogenic shock. These definitions were consistent with previous studies. 5, 6 
Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD) or as median with interquartile range (IQR) based on distribution of data. Tests of normality were carried out using the Shapiro-Wilk test. Comparisons were made with the use of Student's t-test, Mann-Whitney U-test, ANOVA and Kruskal-Wallis test based on normality of the data. Statistical analysis was performed using SPSS version 24 (SPSS Inc, Chicago, IL, USA). A P-value of <0.05 was considered significant. Primary and secondary endpoints were assessed as above and the cumulative probability of an endpoint was analysed using the Kaplan-Meier method with log-rank testing. 24 .6% with non-dihydropyridine calcium channel blocker therapy and 39.5% with disopyramide therapy. Twenty-three patients had undergone dual chamber pacemaker insertion to treat LVOTO and 15 had undergone alcohol septal ablation with no improvement in symptoms.
Patients were divided into groups based on their surgical intervention: Group A (n = 272) SM alone; Group B (n = 33) SM with MV repair; Group C (n = 22) SM with MV replacement; and Group D (n = 20) MV replacement alone. In Group B, 33 patients underwent a SM with MV repair. The repair technique was tailored to the underlying valve abnormality with valve plication (n = 6), edge-to-edge Alfieri repair (n = 10), cleft repair (n = 6), division of papillary muscles (n = 1), and chordal repair (n = 7). Full surgical details were unavailable in three patients undergoing MV repair.
The characteristics of each surgical group are summarised in Table 1 . Patients undergoing MV replacement were older at diagnosis and at the time of surgery with a higher prevalence of hypertension. Group D had a higher prevalence of AF. The mean LV wall thickness prior to surgery was smallest in Group D, with 11 of 20 patients having a maximum LV wall thickness < 17.0 mm. Mitral regurgitation was more severe in those undergoing a MV procedure, particularly in those requiring MV replacement. All patients in Group D had a planned MV replacement. In Group C, 13 of the MV replacements were unplanned and were carried out at the time of intervention due to persistence of mitral regurgitation despite SM and/or MV repair.
. Table 2 . There were four ventricular septal defects (VSD) requiring repair, all of which were in Group A with a maximum LV wall thickness of 15 mm, 16 mm, 18 mm, and 21 mm, respectively. There was one LV rupture of the lateral wall that was repaired successfully at the time of SM. One patient following MV replacement was noted to have a left-to-right shunt on echocardiography post-operatively and was diagnosed with a Gerbode defect, which was successfully repaired surgically. There were two unplanned AV repairs due to AV injury during surgery. All remaining AV procedures were carried out for pre-existing aortic regurgitation or mixed valve disease with mild AS only.
There were eight perioperative strokes and four transient ischaemic attacks. Of these 12 cases, four had previously documented AF and four had new onset AF. Four patients had no documented AF. One patient had an air embolus and one patient had a deep vein thrombosis with an associated patent foramen ovale and paradoxical embolism. Preoperatively the mean left atrial diameter in patients who suffered a perioperative cerebrovascular accident was 50.5 ± 13.7 mm with a mean left atrial area of 41.5 ± 19.1 cm 2 . Twenty-four (6.9%) patients required a perioperative PPM insertion for high grade atrioventricular heart block. Nine (2.6%) patients had an ICD inserted for primary prevention in the perioperative period and one patient for secondary prevention of aborted SCD following an in-hospital cardiac arrest with successful defibrillation.
Symptoms following surgery
In the cohort as a whole, 95.1% of patients described symptoms of dyspnoea preoperatively. Overall, 72.4% of patients in the entire cohort at 1 year described an improvement in symptoms with an improvement of at least one NYHA class. At 1 year, in Group A, the NYHA class improved from 2.5 ± 0.6 to 1.6 ± 0.6 (P < 0.05); in Group B the NYHA class improved from 2.6 ± 0.5 to 1.5 ± 0.6 (P < 0.05); in Group C the NYHA class improved from 2.5 ± 0.6 to 1.7 ± 0.7 (P < 0.05); and in Group D the NYHA class improved from 2.5 ± 0.5 to 1.9 ± 0.7 (P < 0.05). The proportion of patients who responded to therapy with improvement in NYHA class is documented in Figure 1 with a poorer clinical response in Group D and a significant response difference between groups (P < 0.05).
Symptoms other than dyspnoea are described in the supplementary material online, Table S1 . Preoperatively 165 patients (47.6%) described symptoms of exertional chest pain; 114 patients (32.9%) and 46 patients (13.3%) described symptoms of presyncope and syncope, respectively; and 122 patients (35.2%) complained of palpitations. At 1-year follow-up, 26 patients (7.5%) described exertional chest pain, 27 patients (7.8%) had symptoms of presyncope, and 8 (2.3%) patients had further episodes of syncope; 51 patients (14.7%) described symptoms of palpitations.
Changes in echocardiographic parameters at 1 year
The mean resting gradient improved from 71.9 ± 39.6 mmHg preoperatively to 13.4 ± 18.5 mmHg post-operatively (P < 0.05).
. Responders were defined as those improving by at least one NYHA class.
This gradient improved significantly in all groups. At 1 year, 9.3% of patients had a resting gradient >30 mmHg. A further 3.3% had no significant resting gradient but on provocation with Valsalva had a LVOT gradient >50 mmHg. In total, 253 patients had resting LVOTO and 94 patients (73, 8, 6, 7 in Groups A to D, respectively) had latent LVOTO with significant LVOT gradients on provocation only. In patients with latent LVOTO, the mean resting LVOT gradient improved from 25.2 ± 13.0 mmHg preoperatively to 8.4 ± 7.2 mmHg post-operatively (P < 0.05). The mean provoked LVOT gradient in this group improved from 84.8 ± 37.0 mmHg preoperatively to 11.0 ± 9.7 mmHg post-operatively (P < 0.05).
There was a similar reduction in maximum LV wall thickness in all groups except Group D with a significant difference on analysis between groups (P < 0.05). This was similar for septal wall thickness. Left ventricular end-diastolic diameter increased in Groups A and B but was seen to reduce in those undergoing MV replacement in Groups C and D. Ejection fraction reduced in those undergoing SM and increased in Group D. Changes in echocardiographic variables are documented in the supplementary material online, Table S2 . 
Changes in functional status using cardiopulmonary exercise testing
CPET data were available in 123 (45.2%) patients undergoing SM alone. There was no change in per cent predicted or absolute peak oxygen consumption following surgery but there was an improvement in percentage of predicted target heart rate from 70% to 74% (P < 0.05) and in systolic blood pressure response to exercise (32.0 mmHg to 40.4 mmHg) (P < 0.05). Only a minority of patients undergoing MV procedures had a CPET pre-and post-operatively. Data on CPET are shown in the supplementary material online, Table S3 .
Long-term outcomes
Median follow-up was 5.2 years (IQR 1.9-7.9 years). patients were followed by local physicians; 9 (2.6%) patients were lost to follow-up.
Mortality
Excluding perioperative deaths, there were 20 deaths during follow-up (15 in Group A, two in Group B, two in Group C, and one in Group D). There were five cardiovascular deaths, one from SCD, three from HF, and one from a stroke. There were seven non-cardiac deaths and eight patients died of unknown causes. Estimated survival rates for all-cause mortality post-operatively at 1, 5 and 10 years, respectively, were 98. 4 Figure 2 .
Morbidity
At follow-up, 72 patients (20.7%) had documented paroxysmal AF and 31 patients (8.9%) had persistent AF. There were four transient ischaemic attacks and four strokes, three of which were presumed cardioembolic, as shown in Table 3 . The mean left atrial diameter was 51.5 ± 8.0 mm post-operatively in this subgroup.
Nine patients (2.6%) received a PPM and 45 patients (13.0%) an ICD. All ICDs were inserted for primary prophylaxis following regular assessment of their risk profile during follow-up. Nine of these 45 patients undergoing ICD insertion on follow-up had cardiac resynchronization therapy (CRT)-D devices due to development of LV dysfunction. Eleven patients developed syncope, 15 patients developed non-sustained ventricular tachycardia (NSVT) and seven patients developed syncope with NSVT, which significantly changed their risk profile following surgery. Data on the specific indication for ICD therapy were unavailable in three patients. There were 10 CRT-P devices inserted on follow-up. In total, 99 patients had an ICD in situ post-operatively that was either inserted before or after the operation. There were three appropriate ICD shocks for ventricular tachycardia/fibrillation on follow-up; one patient had two appropriate shocks. There were five inappropriate shocks during the follow-up period.
Eleven patients (3.2%) were admitted for the treatment of HF requiring intravenous diuretics. Two of these patients had evidence of LV dysfunction with an ejection fraction <50% on their 5-year echocardiogram. No patient admitted with HF had recurrence of obstruction. The median time to first HF hospitalisation was 5.2 years (IQR 0.9-6.4 years). Sixteen patients (4.6%) underwent a second surgical procedure with a median time to reintervention of 3.0 years (IQR 0.3-5 years): seven redo myectomies, eight MV replacements, one MV repair, and three AV replacements. No patient underwent a heart transplant on follow-up. Of the eight patients who required a redo MV replacement on follow-up, the NYHA class changed from 2.4 ± 0.5 preoperatively to 1.6 ± 0.8 at 1 year and 2.3 ± 0.4 at 5 years. The LVOT gradients reduced from 
Discussion
Most studies of SM in HCM have focused on long-term mortality rather than morbidity. 14, 18, 25 The novel finding in this study is that in spite of low procedural and long-term death rates, the incidence of non-fatal disease-related complications after surgical treatment of LVOTO is relatively high during follow-up, illustrating the need for ongoing clinical surveillance and medical therapy. We also identified an older cohort of patients that have LVOTO associated with milder hypertrophy but severe mitral regurgitation who responded less well to intervention.
Single centre studies and meta-analyses show that SM is an effective procedure with a low mortality rate in high volume specialist centres, but relatively few studies have reported on the outcomes of MV surgery in patients with HCM. 26, 27 The findings in the present study are broadly in line with the published literature in that a reduction in resting LVOTO to less than 30 mmHg was achieved in more than 90% of patients undergoing SM alone, with an operative mortality of approximately 1%. Significant improvements, of >80% in NYHA functional class, are reported from previous studies, with almost 75% of patients overall in this current study showing documented improvement.
14,25 Almost 30% of patients on follow-up had documented AF in keeping with known contemporary data on AF in HCM. 28 Patients who underwent SM and MV repair had similar outcomes to those treated with SM alone, but those who received MV replacements had poorer outcomes with less symptomatic benefit in spite of a similar reduction in LVOT gradients. These findings suggested that patients with LVOTO and other indications for mitral surgery need to be carefully selected for intervention and that further study is required to optimise surgical strategies in this group. Mitral valve replacement as a primary therapy for LVOTO was first advocated in the 1970s, but subsequent studies reported higher rates of perioperative and late mortality compared with SM alone. 29, 30 Nevertheless, MV abnormalities that contribute to LVOTO are common in patients with HCM and, as a result, numerous valve sparing repair procedures have been explored. In the present study, MV replacement was considered to be the most appropriate management in a minority of patients. Although numbers in Group D are small, patients who underwent MV replacement for LVOTO had higher perioperative mortality and stroke rates compared with patients who underwent SM alone, and nearly 60% had no improvement in NYHA class at 1 year. However, individuals who underwent MV replacement were significantly older and had more co-morbidities including AF and hypertension. Their cardiac morphology also differed in that they had less hypertrophy, greater MR and larger left atria. Together these findings suggested that the patients who underwent MV replacement had a more severe cardiac phenotype than those who underwent SM alone and that this situation may account for their poorer surgical outcomes. It is to be noted that MV replacement alone can be a useful approach particularly in those patients with limited hypertrophy and those individuals who are unsuitable for multiple cardiopulmonary bypass runs. Good resolution of LVOT gradients is seen in those individuals who underwent MV replacement. Trends however from this study showed that symptomatic improvement following MV replacement is less than that seen after SM. This caveat should be factored into decision making when planning a surgical approach, but it is important that all cases have an individualised approach.
Very few studies have investigated changes in exercise performance after surgical treatment for LVOTO. In the subset of patients who underwent CPET before and after SM, there was an improvement in systolic blood pressure response but no change in peak oxygen consumption. The lack of improvement in peak oxygen consumption seems counterintuitive given the improvement in NYHA class reported by most patients, but it probably reflects the complex mechanism of exercise limitation in HCM. For example, it is possible that the relief of mitral regurgitation related to systolic anterior motion of the MV and exercise-induced myocardial ischaemia could result in symptomatic improvement without an increase in LV stroke volume sufficient to increase peak oxygen consumption. Similarly, the increase in exercise blood pressure might reflect changes in centrally mediated vascular behaviour during exercise rather than an increase in cardiac output. Given the small number in other groups, conclusions must be guarded and further studies are required in this area.
Limitations
This study consisted of a retrospective analysis of data on patients who had been operated on for LVOTO in a large referral centre for cardiomyopathy. The referral nature of these patients is a limitation inherent to this study; however, our centre receives a wide range of patients from around UK and the vast majority of patients continues to be followed up at our centre. A full data set was not available for conduction abnormalities on ECG.
Conclusions
Septal myectomy for LVOTO is a safe procedure in high volume centres and results in symptomatic improvement in the majority of patients. Ongoing clinical surveillance and medical therapy are still required following surgery as disease-related complications such as AF and HF are common following successful surgical treatment of LVOTO. Mitral valve replacement in patients with LVOTO is associated with higher mortality and morbidity and is less successful in improving symptoms, but the characteristics of patients requiring MV replacement suggest that this group is at higher preoperative risk and has a different phenotype to the majority of patients who undergo surgical treatment for LVOTO.
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